[go: up one dir, main page]

AU2002233929A1 - Compositions of peptide crystals - Google Patents

Compositions of peptide crystals

Info

Publication number
AU2002233929A1
AU2002233929A1 AU2002233929A AU3392902A AU2002233929A1 AU 2002233929 A1 AU2002233929 A1 AU 2002233929A1 AU 2002233929 A AU2002233929 A AU 2002233929A AU 3392902 A AU3392902 A AU 3392902A AU 2002233929 A1 AU2002233929 A1 AU 2002233929A1
Authority
AU
Australia
Prior art keywords
compositions
peptide crystals
crystals
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002233929A
Inventor
Steven Witt Dodd
Kingman Ng
Joseph Vincent Junior Rinella
Eric Alan Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002233929A1 publication Critical patent/AU2002233929A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002233929A 2000-12-13 2001-12-06 Compositions of peptide crystals Abandoned AU2002233929A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25525100P 2000-12-13 2000-12-13
US60/255,251 2000-12-13
PCT/US2001/043188 WO2002047715A2 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Publications (1)

Publication Number Publication Date
AU2002233929A1 true AU2002233929A1 (en) 2002-06-24

Family

ID=22967502

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2002228608A Abandoned AU2002228608A1 (en) 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1
AU2002239262A Abandoned AU2002239262A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals
AU2002233929A Abandoned AU2002233929A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU2002228608A Abandoned AU2002228608A1 (en) 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1
AU2002239262A Abandoned AU2002239262A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Country Status (4)

Country Link
US (1) US7199217B2 (en)
EP (1) EP1351984A2 (en)
AU (3) AU2002228608A1 (en)
WO (3) WO2002048192A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
DK1412384T3 (en) 2001-06-28 2008-04-28 Novo Nordisk As Stable formulation of modified GLP-1
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
ATE494010T1 (en) * 2002-02-27 2011-01-15 Pharmain Corp THERAPEUTIC DELIVERY COMPOSITIONS AND OTHER MATERIALS AND METHODS FOR THE PRODUCTION AND USE THEREOF
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425221T3 (en) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc New methods and compositions for enhanced transmucosal delivery of peptides and proteins
MXPA05013048A (en) * 2003-06-03 2006-03-02 Novo Nordisk As Stabilized pharmaceutical peptide compositions.
BRPI0410972C1 (en) 2003-06-03 2021-05-25 Novo Nordisk As method for increasing the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia
PL1633391T3 (en) 2003-06-03 2012-03-30 Novo Nordisk As Stabilized pharmaceutical peptide compositions
JP5518282B2 (en) * 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス Stable peptide formulation
CN104826116A (en) 2003-11-20 2015-08-12 诺沃挪第克公司 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
RU2413530C9 (en) 2004-11-12 2021-05-18 Ново Нордиск А/С Stable preparations of insulin peptides
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1904525A4 (en) * 2005-06-30 2009-10-21 Ipsen Pharma Glp-1 pharmaceutical compositions
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (en) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 Truncated glucagon-like peptide 1 (sGLP-1), preparation method and application
JP2009520040A (en) * 2005-12-19 2009-05-21 ファーマイン コーポレーション Hydrophobic core carrier composition for delivery of therapeutic agents and methods of making and using the same
AU2007240313B2 (en) 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
MX2009001114A (en) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Osmotic delivery systems and piston assemblies.
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
US20120214965A1 (en) * 2011-02-23 2012-08-23 Elona Biotechnologies Glargine proinsulin and methods of producing glargine insulin analogs therefrom
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EA017849B1 (en) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon/glp-1 receptor co-agonists
CN104000779A (en) 2007-04-23 2014-08-27 精达制药公司 Suspension formulations of insulinotropic peptides and uses thereof
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
PA8830501A1 (en) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
EA020326B9 (en) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Gip-based mixed agonists for treatment of metabolic disorders and obesity
CN102325539A (en) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
CN102459325B (en) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 Gastropin receptor activating glucagon compound
DK2462246T3 (en) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc QUICK ESTABLISHMENT AND / OR END OF SIGNIFICANT STEADY-STATE PHARMACEUTICAL DELIVERY
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
US9096843B2 (en) 2009-12-01 2015-08-04 Novo Nordisk A/S Peptidyl α-hydroxyglycine α-amidating lyases
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp CONJUGATES OF GLUCAGON ANTAGONIST AND GIP AGONIST AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
AU2011224350B2 (en) * 2010-03-09 2015-07-02 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
CN103179976A (en) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
RU2580317C2 (en) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Peptide pro-drugs of amide glucagon superfamily
RU2600440C3 (en) 2010-12-16 2021-12-10 Ново Нордиск А/С SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N- (8- (2-HYDROXYBENZOYL) AMINO) CAPRYLIC ACID SALT
BR112013015389A2 (en) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp glucagon analog displaying gip receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
PE20140724A1 (en) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEPTOR COAGONISTS
CA2839867A1 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
ES2715308T3 (en) 2012-03-22 2019-06-03 Novo Nordisk As Compositions comprising a supply agent and its preparation
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
WO2013170636A1 (en) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 Protein and protein conjugate for diabetes treatment, and applications thereof
ES2871328T3 (en) 2012-06-20 2021-10-28 Novo Nordisk As Tablet formulation comprising a peptide and a delivery agent
JP6311708B2 (en) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
MA53353A (en) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (en) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
BR112020014624A2 (en) 2018-02-02 2020-12-08 Novo Nordisk A/S SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT)
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Use of raman spectroscopy in downstream purification
BR112021006823A2 (en) 2018-10-11 2021-07-27 Intarcia Therapeutics, Inc. human amylin analogue polypeptides and methods of use
PE20230819A1 (en) 2020-02-18 2023-05-19 Novo Nordisk As COMPOSITIONS AND USES OF GLP-1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347374A (en) 1980-07-21 1982-08-31 Merck & Co., Inc. Acid addition salts of N-trityl-α-fluoromethylhistidine enantiomer derivatives
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
WO1987006941A1 (en) * 1986-05-05 1987-11-19 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
AU662731B2 (en) 1991-04-09 1995-09-14 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
JP2575298B2 (en) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド Glucagon-like peptide and insulinotropin derivatives
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CA2336112A1 (en) * 1998-06-30 2000-01-13 Flemming Manique Seeding crystals for the preparation of peptides or proteins
WO2001057084A1 (en) * 2000-01-31 2001-08-09 Novo Nordisk A/S Crystallisation of a glp-1 analogue
BR0113178A (en) 2000-08-02 2004-04-06 Theratechnologies Inc Modified biological peptides with increased potency
DK1355942T3 (en) * 2000-12-07 2008-11-17 Lilly Co Eli GLP-1 fusion proteins

Also Published As

Publication number Publication date
EP1351984A2 (en) 2003-10-15
AU2002228608A1 (en) 2002-06-24
WO2002048192A2 (en) 2002-06-20
WO2002048183A2 (en) 2002-06-20
AU2002239262A1 (en) 2002-06-24
WO2002047715A3 (en) 2003-01-30
WO2002048192A3 (en) 2003-08-07
US7199217B2 (en) 2007-04-03
WO2002047715A2 (en) 2002-06-20
US20040132647A1 (en) 2004-07-08
WO2002048183A3 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2002239262A1 (en) Compositions of peptide crystals
AU4133701A (en) Methods and compositions for peptide synthesis
AU2001286233A1 (en) Cement composition
AU2001234105A1 (en) Cement composition
AU7719100A (en) Compositions of tocol-soluble therapeutics
AU2001233691A1 (en) Antiperspirant compositions
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
AU2001285790A1 (en) Antiperspirant compositions
AU2001244692A1 (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
AU2002217071A1 (en) Novel use of polyhydroxy compounds
EP1407780A4 (en) Pharmaceutically stable hemostatic compositions
AU2001269685A1 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
AU1287100A (en) Peptide inhibitor of browman-birk type
AU1718301A (en) Use of sugar compositions
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001267522A1 (en) Cosmetic compositions containing substituted amide derivatives
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2002362579A1 (en) Tetrapeptide derivative crystals
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2001277750A1 (en) Use of polypeptide
AU2001286584A1 (en) Inhibition of protein-protein interaction
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2002216038A1 (en) Preparation of monofluoroalkenes